These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20890035)

  • 1. [Cytokines in bone diseases. Wnt signal and excessive bone formation].
    Hosoi T
    Clin Calcium; 2010 Oct; 20(10):1526-31. PubMed ID: 20890035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Regulation of bone metabolism by pathogenic mutations and polymorphism in the LRP5-Wnt signaling genes].
    Urano T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():95-100. PubMed ID: 18161089
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cytokines in bone diseases. Wnt signaling and osteoporosis-pseudoglioma syndrome].
    Ozono K
    Clin Calcium; 2010 Oct; 20(10):1520-5. PubMed ID: 20890034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Wnt-beta-catenin signaling in bone metabolism].
    Urano T
    Clin Calcium; 2006 Jan; 16(1):54-60. PubMed ID: 16397351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Wnt signaling and bone metabolism].
    Asaba H; Sakai J
    Clin Calcium; 2005 May; 15(5):813-8. PubMed ID: 15876744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
    van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
    J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.
    Li J; Sarosi I; Cattley RC; Pretorius J; Asuncion F; Grisanti M; Morony S; Adamu S; Geng Z; Qiu W; Kostenuik P; Lacey DL; Simonet WS; Bolon B; Qian X; Shalhoub V; Ominsky MS; Zhu Ke H; Li X; Richards WG
    Bone; 2006 Oct; 39(4):754-66. PubMed ID: 16730481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokines in bone diseases. Bone anabolic action of PTH and role of cytokine].
    Kaji H; Sugimoto T
    Clin Calcium; 2010 Oct; 20(10):1555-61. PubMed ID: 20890039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton.
    Koay MA; Brown MA
    Trends Mol Med; 2005 Mar; 11(3):129-37. PubMed ID: 15760771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt signaling: a key regulator of bone mass.
    Baron R; Rawadi G; Roman-Roman S
    Curr Top Dev Biol; 2006; 76():103-27. PubMed ID: 17118265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.
    Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W
    Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-sclerostin antibodies].
    Okazaki R
    Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high bone mass family--the role of Wnt/Lrp5 signaling in the regulation of bone mass.
    Johnson ML
    J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):135-8. PubMed ID: 15615112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR structure of the Wnt modulator protein Sclerostin.
    Weidauer SE; Schmieder P; Beerbaum M; Schmitz W; Oschkinat H; Mueller TD
    Biochem Biophys Res Commun; 2009 Feb; 380(1):160-5. PubMed ID: 19166819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
    Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
    Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wnt signaling pathway and bone metabolism.
    Johnson ML; Kamel MA
    Curr Opin Rheumatol; 2007 Jul; 19(4):376-82. PubMed ID: 17551370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the Wnt signaling pathway in osteoblast commitment and differentiation.
    Yavropoulou MP; Yovos JG
    Hormones (Athens); 2007; 6(4):279-94. PubMed ID: 18055419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
    Löwik CW; van Bezooijen RL
    J Musculoskelet Neuronal Interact; 2006; 6(4):357. PubMed ID: 17185823
    [No Abstract]   [Full Text] [Related]  

  • 20. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.